Reviewing Entrada Therapeutics (NASDAQ:TRDA) and Oncotelic Therapeutics (OTCMKTS:OTLC)

Entrada Therapeutics (NASDAQ:TRDA) and Oncotelic Therapeutics (OTCMKTS:OTLC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Risk and Volatility

Entrada Therapeutics has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500. Comparatively, Oncotelic Therapeutics has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.

Earnings & Valuation

This table compares Entrada Therapeutics and Oncotelic Therapeutics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$129.01 million	3.75	-$6.68 million	($0.26)	-55.23
Oncotelic Therapeutics	$70,000.00	220.69	-$7.90 million	N/A	N/A

Entrada Therapeutics has higher revenue and earnings than Oncotelic Therapeutics.

Profitability

This table compares Entrada Therapeutics and Oncotelic Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-5.18%	-2.89%	-1.39%
Oncotelic Therapeutics	N/A	-57.94%	-24.83%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Entrada Therapeutics and Oncotelic Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	0	0	2	0	3.00
Oncotelic Therapeutics	0	0	0	0	N/A

Entrada Therapeutics presently has a consensus price target of $21.00, indicating a potential upside of 46.24%. Given Entrada Therapeutics’ higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Oncotelic Therapeutics.

Institutional and Insider Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Comparatively, 39.2% of Oncotelic Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Entrada Therapeutics beats Oncotelic Therapeutics on 7 of the 11 factors compared between the two stocks.

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About Oncotelic Therapeutics

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.